The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 randomized study of rintatolimod following FOLFIRINOX in patients with locally advanced pancreatic adenocarcinoma.
 
Kelsey Klute
Consulting or Advisory Role - Agenus; Cancer Expert Now; Daiichi Sankyo/Lilly; Oncolytics; Pfizer
Research Funding - AIM ImmunoTech (Inst); AstraZeneca (Inst); FibroGen (Inst); RenovoRx (Inst)
 
Vincent J. Picozzi
Stock and Other Ownership Interests - Amgen; Cigna; Iovance Biotherapeutics; Johnson & Johnson; McKesson; Thermo Fisher Scientific
Consulting or Advisory Role - TriSalus Life Sciences
Research Funding - Abbvie; Amal Therapeutics; Astellas Pharma; FibroGen; Ipsen; NovoCure
 
Nashat Gabrail
Consulting or Advisory Role - Celgene; Chemiocare
Speakers' Bureau - Janssen Oncology; Janssen Oncology; Janssen Oncology; Karyopharm Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tesaro/GSK
Research Funding - Amgen (Inst); Bayer (Inst); Chemiocare (Inst); Chemiocare (Inst); Kartos Therapeutics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Oncology Supply
 
Michael A. Hollingsworth
Stock and Other Ownership Interests - Sanguine Diagnostics and Therapeutics
Research Funding - AIM ImmunoTech (Inst); GlycoMimetics (Inst)
 
Christopher McAleer
Employment - AIM ImmunoTech
Patents, Royalties, Other Intellectual Property - I have patents currently pending with Aim Immunotech
 
Diane Young
Employment - AIM ImmunoTech Inc.
 
David Rodney Strayer
Employment - AIM ImmunoTech Inc.